TickerKhojComparison · NSE · data 2026-11-02
Jagsonpal Pharmaceuticals Ltd. vs NGL Fine-Chem Ltd.
In plain words
Size: NGL Fine-Chem Ltd. is about 1.1 times the market value of Jagsonpal Pharmaceuticals Ltd..
Valuation (P/E): Jagsonpal Pharmaceuticals Ltd. 32.4 vs NGL Fine-Chem Ltd. 27.8.
Profit growth over 3 years: NGL Fine-Chem Ltd. 32.9% a year vs Jagsonpal Pharmaceuticals Ltd. 17.3% a year.
Debt to equity: NGL Fine-Chem Ltd. 0.37 vs Jagsonpal Pharmaceuticals Ltd. 0.03.
Differences in the numbers, not a recommendation of either stock.
Side by side
| JAGSNPHARM | NGLFINE | |
|---|---|---|
| Price | ₹215.99 | ₹2,574 |
| Market cap | ₹1,433 cr | ₹1,576 cr |
| P/E | 32.4 | 27.8 |
| P/B | 5.9 | — |
| ROE | 16.7% | 15.7% |
| ROCE | 18.1% | 17.1% |
| Debt / equity | 0.03 | 0.37 |
| Operating margin | 16.6% | 11.9% |
| Dividend yield | 1.15% | 0.07% |
| Sales growth, 3 years (yearly) | 6.7% | 21.7% |
| Profit growth, 3 years (yearly) | 17.3% | 32.9% |
| 1-year return | -2.5% | 68.8% |
| Revenue, last 12 months | ₹316 cr | ₹536 cr |
| Net profit, last 12 months | ₹45 cr | ₹57 cr |
| Latest quarter | Sept 2026 | Jun 2026 |
| Quarter net profit | ₹12 cr | ₹18 cr |
| Quarter profit vs a year earlier | -2.2% | +99.1% |
| Promoter holding | 68.81% | 72.49% |
| Health check | Strong (6.7/10) | Strong (8.3/10) |
Common questions
Which has a higher P/E, Jagsonpal Pharmaceuticals Ltd. or NGL Fine-Chem Ltd.?
Jagsonpal Pharmaceuticals Ltd. trades at the higher P/E (32.4 against 27.8). A higher P/E means the market pays more for each rupee of past earnings; on its own it does not say which is better.
Which earns a higher return on equity?
Jagsonpal Pharmaceuticals Ltd. (16.7% against 15.7%).
Which carries more debt?
NGL Fine-Chem Ltd. has the higher debt-to-equity ratio (0.37 against 0.03).